Lifecore Biomedical (LFCR) Registration filing summary

Company overview and business model

• Operates as a fully integrated contract development and manufacturing organization specializing in cGMP manufacturing and aseptic filling of complex sterile injectable pharmaceuticals and medical devices, with expertise in non-animal-sourced hyaluronic acid (HA) production and highly viscous injectables for various medical applications.

• Recognized as a leading U.S. manufacturer of pharmaceutical-grade HA, leveraging proprietary fermentation processes developed since 1981 for both bulk and formulated products.

• Incorporated in California in 1986 and reincorporated in Delaware in 2008; common stock is listed on Nasdaq under the symbol “LFCR.”

Financial performance and metrics

• Completed private placements in 2022, 2023, and 2024, raising approximately $5.0 million, $38.75 million, and $24.3 million, respectively, through sales of common and preferred stock.

• As of September 19, 2025, the last reported sale price of common stock was $7.87 per share.

• The company is classified as a "smaller reporting company" under federal securities laws, subject to reduced reporting requirements.

Use of proceeds and capital allocation

• Net proceeds from the sale of securities will be used as set forth in the applicable prospectus supplement; no proceeds will be received from the resale of shares by selling stockholders.